Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; 16 of the 62 sources its claims cite were checked for support.
Abstract
Elimination of amyloid-ss peptide (Ass) from the brain is poorly understood. After intracerebral microinjections in young mice, (125)I-Ass(1-40) was rapidly removed from the brain (t(1/2) </= 25 minutes), mainly by vascular transport across the blood-brain barrier (BBB). The efflux transport system for Ass(1-40) at the BBB was half saturated at 15.3 nM, and the maximal transport capacity was reached between 70 nM and 100 nM. Ass(1-40) clearance was substantially inhibited by the receptor-associated protein, and by antibodies against LDL receptor-related protein-1 (LRP-1) and alpha(2)-macroglobulin (alpha(2)M). As compared to adult wild-type mice, clearance was significantly reduced in young and old apolipoprotein E (apoE) knockout mice, and in old wild-type mice. There was no evidence that Ass was metabolized in brain interstitial fluid and degraded to smaller peptide fragments and amino acids before its transport across the BBB into the circulation. LRP-1, although abundant in brain microvessels in young mice, was downregulated in older animals, and this downregulation correlated with regional Ass accumulation in brains of Alzheimer's disease (AD) patients. We conclude that the BBB removes Ass from the brain largely via age-dependent, LRP-1-mediated transport that is influenced by alpha(2)M and/or apoE, and may be impaired in AD.
Overview
CoChat Summary
TL;DR
In mice, intracerebrally injected ¹²⁵I-Aβ1-40 is rapidly cleared from brain, mainly by LRP-1-mediated transport across the blood-brain barrier, with clearance influenced by α2M and apoE. LRP-1 downregulation in older mice and in Alzheimer’s disease brain regions correlates with Aβ accumulation, suggesting impaired vascular clearance may contribute to AD.
Key findings
- After intracerebral microinjection in young mice, total brain efflux half-time for ¹²⁵I-Aβ1-40 was 25.5 ± 2.0 minutes versus 239.0 ± 12.5 minutes for [¹⁴C]inulin (9.4-fold difference); BBB transport accounted for 73.8% of efflux, ISF bulk flow 10.7%, and 15.6% remained retained at 60 nM.
- Aβ1-40 clearance was concentration-dependent, half-saturated at 15.3 nM, and maximal between 70 nM and 100 nM. Anti-LRP-1 antibody inhibited clearance by about 55% (58% at 12 nM and 53% at 60 nM), RAP inhibited by 30–44%, and anti-α2M inhibited by 25%; anti-LRP-2 and anti-RAGE had no effect.
- There was no evidence of significant Aβ1-40 degradation in brain ISF before transport: injected peptide was >97% intact, 93.7% remained intact at 60 minutes, and only 4.2–9.9% of brain ¹²⁵I radioactivity was non-TCA-precipitable within 270 minutes; plasma degradation increased from 37.6% to 58.3% between 15 and 120 minutes.
- Clearance was reduced in apoE knockout and older mice: 30% reduction in young apoE KO mice, about 55% and 40% reductions in 9-month-old wild-type and apoE KO mice at 12 nM, and 46% reduction in 9-month-old apoE KO mice at 60 nM. LRP-1-positive brain vessels dropped from 94% in 2-month-old mice to 52% in 9-month-old mice, and reduced LRP-1 staining in AD frontal cortex correlated with regional Aβ accumulation.
Methods
- Male C57BL/6 wild-type and apoE knockout mice at 8–10 weeks and 9–10 months received intracerebral microinjections into the right caudate nucleus of ¹²⁵I-Aβ1-40 (0.05–120 nM) plus [¹⁴C]inulin; clearance was measured from 10 to 300 minutes, with dose and inhibitor studies at 30 minutes.
- Radioactivity was analyzed by TCA precipitation, HPLC, and SDS-PAGE; compartmental modeling separated BBB transport, ISF bulk flow, and brain retention. Inhibitors included anti-LRP-1 R777, RAP, anti-α2M, anti-LRP-2, anti-RAGE, fucoidin, and BCH.
- Immunocytochemistry was performed in mouse brain and human frontal cortex/cerebellum from 3 AD patients and 3 age-matched controls (postmortem 4–7 hours), using antibodies against LRP-1, α2M, Aβ1-40/1-42, and CD105.
Limitations
- The paper does not state limitations explicitly. Evident from the text: the mouse clearance model uses synthetic ¹²⁵I-Aβ1-40 and intracerebral injection, which may not fully reflect endogenous Aβ production and clearance.
- Evident: human data are correlational and based on only 3 AD patients and 3 controls; LRP-1 involvement is inferred from antibody/RAP inhibition and immunostaining rather than direct transport assays.
- Evident: the identity of an alternative low-concentration BBB transport mechanism remains unknown, α2M staining cannot distinguish circulating from microvessel-associated α2M, and age comparisons are limited to young versus 9-month-old mice.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
12 Valid · 0 Not valid · 21 Not checked · 114 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Previous studies from our laboratory and others have demonstrated a major role of the BBB in determining the concentrations of A b in the CNS by regulating transport of circulating A b (33, 39, 49-51, 62-66).”
What the sources say
- Partly supportedcites [33] Mackic, 1998, J Clin Invest sourceExperimental — accuracy not yet measured
The Discussion reports transport of circulating Aβ across a human BBB cell model and says that this transport would tend to increase Aβ accumulation in the brain. It does not demonstrate that the BBB has a major role in determining CNS Aβ concentrations in vivo; the paper describes that broader implication as likely. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s opening summary (page not specified in our copy) reports transport of Aβ–apolipoprotein J complexes across the blood–brain barrier into brain tissue in a guinea pig model. It does not establish that this transport has a major role in determining overall CNS Aβ concentrations, as the citing sentence claims. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [49] Maness, 1994, Life Sci source
- Not checked — no full text of the sourcecites [50] Poduslo, 1997, Neurobiol Dis source
- Not checked — no full text of the sourcecites [51] Martel, 1997, J Neurochem source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Binding/uptake studies in mouse embryonic fibroblasts (wild type and deficient in LRP-1), confirmed that free A b is not a ligand for LRP-1 (37, 45).”
What the sources say
- Partly supportedcites [37] Narita, 1997, J Neurochem sourceExperimental — accuracy not yet measured
The Abstract and Discussion report that free Aβ degradation was not inhibited by RAP and describe it as LRP-independent. But Table 1 tested free Aβ in human U87 glioblastoma cells; the mouse embryonic fibroblast comparison tested Aβ complexed with α2-macroglobulin, not free Aβ. Thus the paper supports the LRP-independent uptake conclusion, but not the claim that the fibroblast studies confirmed it. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [45] Kounnas, 1995, Cell source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Because normal aging is associated with A b accumulation in the brain (1)”
What the sources say
- Supportedcites [1] Wisniewski, 1997, Neurobiol Dis source
The section on the amyloid cascade hypothesis says that extensive Aβ-containing preamyloid deposits can be found in aged individuals with no reported clinical symptoms. This supports the claim that brain Aβ accumulation is associated with normal aging; the paper does not say it occurs in every older person. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This makes re-entry of radiolabeled A b into the brain very unlikely, because the blood-to-brain transport of A b normally operates down the concentration gradient (39, 62-65).”
What the sources say
- Partly supportedcites [39] Zlokovic, 1996, Proc Natl Acad Sci USA sourceExperimental — accuracy not yet measured
The paper’s study summary (page not identified in our copy) reports transport of Aβ–apolipoprotein J complexes from blood into brain parenchyma. It does not say that this transport normally follows a concentration gradient or that re-entry of radiolabeled Aβ is unlikely. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [62] Zlokovic, 1993, Biochem Biophys Res Commun source
- Not checked — no full text of the sourcecites [63] Ghilardi, 1996, Neuroreport source
- Not checked — no full text of the sourcecites [64] Shayo, 1997, Life Sci source
- Partly supportedcites [65] Martel, 1996, Neurosci Lett sourceExperimental — accuracy not yet measured
The discussion passage in our copy (labeled Abstract; page unavailable) says that a lower soluble Aβ42 concentration on the brain side of the BBB would provide a thermodynamic impetus for transport from capillaries into brain. It does not establish that blood-to-brain transport normally operates down a concentration gradient or that re-entry of radiolabeled Aβ is very unlikely; the study also observed uptake of radiolabeled Aβ in perfused guinea-pig brains. (LLM, conf=0.80)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“RAP, a chaperone protein that facilitates proper folding and subsequent trafficking of LRP-1 and LRP-2 (69), also inhibited A b clearance.”
What the sources say
- Partly supportedcites [69] Bu, 1996, J Biol Chem sourceExperimental — accuracy not yet measured
The citation is attached to the description of RAP as a folding and trafficking chaperone, not to the citing authors’ statement that RAP inhibited Aβ clearance. The paper’s Discussion supports that role for LRP, but does not establish it for the separate receptor LRP-2; its use of “LRP2” denotes a domain of LRP. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
92 more claims
Create a free account to see all 147 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 30
- Probably not a substantial claim. 25
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, transport studies using radiolabeled and unlabeled Alzheimer's A 𝛃 peptide have shown that under physiological conditions, the perivascular ISF flow contributes to 15-20% of A 𝛃 clearance from the mouse brain (58, 535, 659), whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 binds Alzheimer's A 𝛃 toxin and mediates its brain-to-blood clearance (58, 137, 535, 561).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several groups have reported that trans-BBB efflux of Aβ into peripheral blood circulation is one of the main pathways of physiological clearance with ApoE, ApoJ, and ApoA1 as chaperones27,31,32.”
From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“LRP1 and LRP2 are expressed in brain endothelium and colocalize mainly on the abluminal side of the BBB in humans and rodents (137, 404, 535, 607, 682).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas 8085% is removed by transvascular BBB transport.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [535]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results · p. 5
“The HPLC analysis of brain radioactivity confirmed the TCA results by indicating that 93.7% of the peptide remains intact in brain ISF at 60 minutes (Figure 3b, right).”
§ Figure 3 · p. 6
“( b ) Left panel shows HPLC elution profile of brain tissue 60 minutes after intracerebral microinjection of 125 I-A b 1-40 (60 nM). Separation was performed for 30 mg of brain tissue on a reverse-phase HPLC column, using a 30-minute linear gradient of 25-83% acetonitrile in 0.1% TFA, pH 2. 125 I-A b 1-40 eluted at 52%, corresponding to the elution time of A b 1-40 standard. Right panel shows SDS-PAGE analysis”
Citations
Cites
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · cited 10×
“No anti-Aβ1-40–positive or Aβ1-42–positive staining was seen in either AD or control tissues.”
BackgroundInfluentialCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · cited 2×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundRAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 9×
“In contrast, anti–LRP-2 Ab (Figure 4b) and anti-RAGE Ab (Figure 4c) did not affect Aβ clearance.”
BackgroundInfluentialIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundSelf-citationHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · cited 1×
“Because normal aging is associated with Aβ accumulation in the brain (1), and there is a significant, timedependent, and progressive accumulation of the peptide with age in transgenic APP animals (54, 55), we postulated that Aβ clearance mechanisms might be impaired in older animals, and are also possibly impaired in…”
BackgroundAlzheimer's Disease--Genotypes, Phenotype, and Treatments
Selkoe, D. J. (1997) · Science · doi:10.1126/science.275.5300.630 · Cited by 875 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
BackgroundIwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E., Kawashima-Morishima, M., Lee, H.-J., Hama, E., Sekine-Aizawa, Y., et al. (2000) · Nature Medicine · doi:10.1038/72237 · Cited by 867 · cited 8×
“However, the physiological relevance of the proposed degradation mechanism for Aβ1-42 (28) remains unclear, because the peptide was studied at extremely high concentrations (∼ 240 μM) that are not found even in brains with severe β-amyloidosis (30).”
BackgroundMethodResultInfluentialThe cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease
Selkoe, D. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01363-4 · Cited by 862 · cited 1×
“β-amyloid (1-42) is a major component of cere-”
Background
Research works printed but not linked: 4
- Suzuki, 1994, Am J Pathol, 145, 452
- Urmoneit, 1997, Lab Invest, 77, 157
- Yamada, 1991, Am J Physiol, 261, H1197
- Kounnas, 1994, In Vivo, 8, 343
Cited by
Items 701–800 of 1,448
NEUROLOGICAL INFECTION AND INFLAMMATION
Bone, I. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.034249 · Cited by 42
Nonaka, N., Banks, W. A., Mizushima, H., Shioda, S., & Morley, J. E. (2002) · Peptides · doi:10.1016/s0196-9781(02)00248-6 · Cited by 42
Madadi, S., Schwarzenbach, H., Saidijam, M., Mahjub, R., & Soleimani, M. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0354-3 · Cited by 41
Glymphatics and meningeal lymphatics unlock the brain-immune code
Kim, M. W., & Kipnis, J. (2025) · Immunity · doi:10.1016/j.immuni.2025.03.006 · Cited by 45
Cellular Prion Protein Participates in Amyloid-β Transcytosis across the Blood—Brain Barrier
Pflanzner, T., Petsch, B., André-Dohmen, B., Müller-Schiffmann, A., Tschickardt, S., Weggen, S., Stitz, L., Korth, C., & Pietrzik, C. U. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.7 · Cited by 39
Vascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease
Galvan, V., & Hart, M. J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.11.010 · Cited by 40
“by antibody or receptor-associated protein binding reduces (but does not abolish) Aβ clearance [105].”
Primate-specific miR-603 is implicated in the risk and pathogenesis of Alzheimer's disease
Zhang, C., Lu, J., Liu, B., Cui, Q., & Wang, Y. (2016) · Aging · doi:10.18632/aging.100887 · Cited by 39
“LRP1 is an important molecule involved in the pathogenesis of AD by modulating APP processing and Aβ generation [26, 27] and serving as a powerful Aβefflux driver of brain through pathways that could be precluded by LRPAP1 [28-30].”
BackgroundModulation of Alzheimer's amyloid β peptide oligomerization and toxicity by extracellular Hsp70
Rivera, I., Capone, R. F., Cauvi, D. M., Arispe, N. J., & Maio, A. D. (2017) · Cell Stress and Chaperones · doi:10.1007/s12192-017-0839-0 · Cited by 43
Tajbakhsh, A., Read, M., Barreto, G. E., Ávila-Rodriguez, M., Gheibi-Hayat, S. M., & Sahebkar, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173873 · Cited by 41
Bajaj, S., Jain, S., Vyas, P., Bawa, S., & Vohora, D. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.06.022 · Cited by 44
Therapeutic approaches for prion and Alzheimer's diseases
Wısnıewskı, T., & Sigurdsson, E. M. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05919.x · Cited by 47
Takata, K., Kitamura, Y., Tsuchiya, D., Kawasaki, T., Taniguchi, T., & Shimohama, S. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00447-6 · Cited by 44
β-Amyloid Aggregation in Human Brains With Cerebrovascular Lesions
Aho, L., Jolkkonen, J., & Alafuzoff, I. (2006) · Stroke · doi:10.1161/01.str.0000248777.44128.93 · Cited by 40
Uchida, K. (2022) · Cells · doi:10.3390/cells11050919 · Cited by 43
Lung endothelium, tau, and amyloids in health and disease
Balczon, R., Lin, M. T., Voth, S. B., Nelson, A. R., Schupp, J. C., Wagener, B. M., Pittet, J., & Stevens, T. (2023) · Physiological Reviews · doi:10.1152/physrev.00006.2023 · Cited by 40
The vascular contribution to cognitive decline in ageing and dementia
Anderle, S., Dixon, M., Quintela‐López, T., Sideris-Lampretsas, G., & Attwell, D. (2025) · Nature reviews. Neuroscience · doi:10.1038/s41583-025-00950-1 · Cited by 53
“…across endothelial cells into the blood, a process that can be mediated by low-density lipoprotein receptor-related protein 1 (LRP1) transporters 115 , and partly as a result of spontaneous blood vessel diameter oscillations 116 that promote the movement of fluid and solutes into the spaces…”
Modeling Alzheimer’s disease with human iPS cells: advancements, lessons, and applications
Essayan-Perez, S., Zhou, B., Nabet, A. M., Wernig, M., & Huang, Y. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104503 · Cited by 45
Pan, J., He, R., Huo, Q., Shi, Y., & Zhao, L. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03076-1 · Cited by 45
Macromolecules involved in production and metabolism of beta-amyl oid at the brain barriers
Crossgrove, J. S., Smith, E. L., & Zheng, W. (2007) · Brain Research · doi:10.1016/j.brainres.2006.12.022 · Cited by 42
“The ability of the choroid plexus to produce and degrade beta-amyloid, in addition to its transport function, suggests a vital role of this tissue in maintaining betaamyloid homeostasis.”
BackgroundBrain amyloid accumulates in aged rats with kaolin-induced hydrocephalus
Klinge, P. M., Samii, A., Niescken, S., Brinker, T., & Silverberg, G. D. (2006) · NeuroReport · doi:10.1097/00001756-200604240-00020 · Cited by 40
“With aging, however, LRP-1 transport is reduced by 50% [8].”
BackgroundAn update on the toxicity of Aβ in Alzheimer’s disease
Götz, J., Ittner, L. M., Schönrock, N., & Cappai, R. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3016 · Cited by 50
“LRP, apoE and the serum protein α2-macroglobulin (α2M) probably modulate Aβ toxicity via clearance of apoE:Aβ and α2M:Aβ complexes or Aβ alone from the brain and hence reduce Aβ levels (Shibata et al 2000; Deane et al 2004).”
BackgroundHereditary and Sporadic Forms of Aβ-Cerebrovascular Amyloidosis and Relevant Transgenic Mouse Models
Kumar-Singh, S. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10041872 · Cited by 38
Hu, T., Chen, C., Huang, G., & Yang, X. (2016) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2016.04.159 · Cited by 45
Pharmacogenomics for the treatment of dementia
Cacabelos, R. (2002) · Annals of Medicine · doi:10.1080/078538902320772115 · Cited by 42
Cerebral sterile inflammation in neurodegenerative diseases
Otani, K., & Shichita, T. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00137-4 · Cited by 39
The vascular contribution of apolipoprotein E to Alzheimer’s disease
Chen, F., Zhao, J., Meng, F., He, F., Ni, J., & Fu, Y. (2024) · Brain · doi:10.1093/brain/awae156 · Cited by 41
Correlations of amyloid-β concentrations between CSF and plasma in acute Alzheimer mouse model
Cho, S. M., Kim, H. V., Lee, S., Kim, H. Y., Kim, W., Kim, T. S., Kim, D. J., & Kim, Y. S. (2014) · Scientific Reports · doi:10.1038/srep06777 · Cited by 39
“Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma.”
BackgroundA β-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment
Montoliu-Gaya, L., & Villegas, S. (2016) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2016.11 · Cited by 37
Ntsapi, C., Lumkwana, D., Swart, C., du Toit, A., & Loos, B. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.002 · Cited by 43
Endocrine Risk Factors for Cognitive Impairment
Moon, J. H. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.2.185 · Cited by 41
Functional Genomics meets neurodegenerative disorders
David, D. C., Hoerndli, F. J., & Götz, J. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.07.001 · Cited by 41
Infante, R., Infante, M., Pastore, D., Pacifici, F., Chiereghin, F., Malatesta, G., Donadel, G., Tesauro, M., & Della‐Morte, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417323 · Cited by 39
“It is worth reminding that P-gp and LRP1 have been reported as major A β transport proteins mediating the A β removal from the brain across the blood-brain barrier [77,78].”
BackgroundWang, H., Chen, F., Zhong, K. L., Tang, S. S., Hu, M. Y., Long, Y., Miao, M. X., Liao, J. M., Sun, H. B., & Hong, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13378 · Cited by 41
“RAGE, present at the lumina of the endothelial cytoplasm, is thought to transport blood Aβ into the brain, while LRP1, located at the ablumina of the endothelial cytoplasm, transports Aβ out of the brain (Shibata et al., 2000; Deane et al., 2003).”
BackgroundMethodInfluentialKim, D.-K., Park, J., & Choi, B. (2014) · The Journal of Toxicological Sciences · doi:10.2131/jts.39.625 · Cited by 38
“The receptor for advanced glycation end products (RAGE) is a key mediator of the influx of free Aβ influx from interstitial fluid into the brain (Shibata et al., 2000; Deane et al., 2003).”
BackgroundMazzitelli, S., Filipello, F., Rasile, M., Lauranzano, E., Cucuzza, C. S., Tamborini, M., Pozzi, D., Barajon, I., Giorgino, T., Natalello, A., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0381-9 · Cited by 39
Aging of the Vascular System and Neural Diseases
Watanabe, C., Imaizumi, T., Kawai, H., Suda, K., Honma, Y., Ichihashi, M., Ema, M., & Mizutani, K. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.557384 · Cited by 43
“, 2016), and its expression is further reduced in AD (Kang et al., 2000; Shibata et al., 2000).”
Background“What Doesn’t Kill You Makes You Stronger”: Future Applications of Amyloid Aggregates in Biomedicine
Abdelrahman, S., Alghrably, M., Lachowicz, J. I., Emwas, A.-H. M., Hauser, C. A. E., & Jaremko, M. (2020) · Molecules · doi:10.3390/molecules25225245 · Cited by 41
“Many reports have correlated defects in the clearance mechanism with the onset of amyloid plaques, rather than overproduction of amyloid beta as was previously suggested [42,43].”
BackgroundPalmer, J. C., Kehoe, P. G., & Love, S. (2010) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2010.01084.x · Cited by 38
Andrieux, K., & Couvreur, P. (2013) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2013.04.001 · Cited by 40
Effect and Mechanism of Acupuncture on Alzheimer’s Disease
Zeng, B., Salvage, S., & Jenner, P. G. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-411545-3.00009-2 · Cited by 39
Urayama, A., Moreno-Gonzalez, I., Morales-Scheihing, D., Kharat, V., Pritzkow, S., & Soto, C. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01679-4 · Cited by 37
“Monomeric and oligomeric Aβ peptides can cross the bloodbrain barrier in both directions [11, 12].”
BackgroundCerebral β-Amyloid Angiopathy Is Associated with Earlier Dementia Onset in Alzheimer's Disease
Vidoni, E. D., Yeh, H.-W., Morris, J. K., Newell, K. L., Alqahtani, A., Burns, N. C., Burns, J. M., & Billinger, S. A. (2016) · Neurodegenerative Diseases · doi:10.1159/000441919 · Cited by 37
Role of Microglia in Regulating Cholesterol and Tau Pathology in Alzheimer’s Disease
Nanjundaiah, S., Chidambaram, H., Chandrashekar, M., & Chinnathambi, S. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00883-6 · Cited by 36
Lee, J., Lee, H., Lee, H. G., Shin, M., Shin, M.-G., Seo, J., Lee, E. J., Park, S. A., & Park, S. (2023) · Nature Communications · doi:10.1038/s41467-023-44319-3 · Cited by 42
“The internalized complexes are routed to the trans-cytotic pathway by RAB5 and RAB11, and released into the circulating bloodstream 15,17 – 21, 23, 28, 29 .”
Novel and rare functional genomic variants in multiple autoimmune syndrome and Sjögren’s syndrome
Johar, A., Mastronardi, C. A., Rojas‐Villarraga, A., Patel, H. R., Chuah, A., Peng, K., Higgins, A., Milburn, P. J., Palmer, S., Silva-Lara, M. F., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0525-x · Cited by 41
“The crucial anti-inflammatory role of LRP1 in counteracting deleterious effects of neurodegenerative diseases has been previously reported [25, 28].”
BackgroundSevoflurane alters the expression of receptors and enzymes involved in A β clearance in rats
LIU, Y., GAO, M., MA, L., ZHANG, L., & PAN, N. (2013) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.12098 · Cited by 38
“Studies have suggested that Ab transport at the BBB is dominated by the receptor for low-density lipoprotein receptor-related protein 1 (LRP-1) and the receptor for advanced glycation end products (RAGE) protein, which demonstrate an ability to rapidly transport circulating free Ab into the CNS and brain-derived Ab in…”
BackgroundFrom the Blood to the Central Nervous System
Fullstone, G., Nyberg, S., Tian, X., & Battaglia, G. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.06.001 · Cited by 38
Valkenburgh, J. S. V., Meuret, C. J., Martinez, A. E., Kodancha, V., Solomon, V. A., Chen, K., & Yassine, H. N. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.700847 · Cited by 41
The Imbalance of Vascular Molecules in Alzheimer's Disease
Bell, R. D. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121060 · Cited by 34
Association of ApoE and LRP mRNA levels with dementia and AD neuropathology
Akram, A., Schmeidler, J., Katsel, P., Hof, P. R., & Haroutunian, V. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.04.010 · Cited by 38
“In particular, LRP-mediated ransport of A /ApoE complex across the blood-brain barrier (BBB) is a major pathway of A clearance from the brain to the periphery (Shibata et al., 2000; Tanzi et al., 2004).”
BackgroundTo, A. W. M., Ribe, E. M., Chuang, T. T., Schroeder, J. E., & Lovestone, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016991 · Cited by 37
“The idea that APOE KOs cannot clear Ab from brain has been suggested [75] and implies that the clearance of Ab from the brain to the periphery requires apoE [74] and is mediated by transport of apoE-Ab complexes across the BBB via LRP-1 [75].”
BackgroundNovel approaches for immunotherapeutic intervention in Alzheimer's disease
Vasilevko, V., & Cribbs, D. H. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.03.019 · Cited by 39
Aβ species, including IsoAsp23 Aβ, in Iowa-type familial cerebral amyloid angiopathy
Shin, Y., Cho, H. J., Fukumoto, H., Shimizu, T., Shirasawa, T., Greenberg, S. M., & Rebeck, W. G. (2003) · Acta Neuropathologica · doi:10.1007/s00401-002-0639-0 · Cited by 42
“Wild-type Aβ is transported from the brain across cortical or meningeal vessels [ 35 ], while more fibrillogenic, mutant Aβ is cleared more inefficiently [30].”
BackgroundMolecular basis of selective amyloid‐β degrading enzymes in Alzheimer's disease
Żukowska, J., Moss, S. J., Subramanian, V., & Acharya, K. R. (2023) · FEBS Journal · doi:10.1111/febs.16939 · Cited by 44
“Non-enzymatic mechanisms include interstitial fluid drainage [95], uptake by microglial phagocytosis [96 – 98] and transport across the blood – brain barrier [99,100].”
Blood–Brain Barrier ( BBB ) Dysfunction in CNS Diseases: Paying Attention to Pericytes
Yu, T., Wang, Z., Chen, Y., Xiang, Y., Wu, M., Zhang, M., Yin, X., & Chen, Z. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70422 · Cited by 41
“However, its specific mechanism in AD has not been fully elucidated, especially the changes in LRP-1 function at different stages of AD [127].”
Bandara, E. M. S., Asih, P. R., Pedrini, S., Hone, E., Fernando, W. M. A. D. B., & Martins, R. N. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05219-3 · Cited by 38
“While the BBB, blood-CSF, and arachnoid barriers generally restrict the movement of large proteins [125, 126], neuroinflammation or CNS injury can compromise these barriers, allowing GFAP to enter circulation [127–129].”
Ruzali, W. A. W., Kehoe, P. G., & Love, S. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121336 · Cited by 34
Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease
Tomita, T. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.01.001 · Cited by 37
Enhanced interstitial fluid drainage in the hippocampus of spontaneously hypertensive rats
Bedussi, B., Naessens, D. M. P., de Vos, J., Olde Engberink, R., Wilhelmus, M. M. M., Richard, E., ten Hove, M., vanBavel, E., & Bakker, E. N. T. P. (2017) · Scientific Reports · doi:10.1038/s41598-017-00861-x · Cited by 36
Mauro, P. P. D., Cascante, A., Brugada-Vilà, P., Gómez‐Vallejo, V., Llop, J., & Borrós, S. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.10.022 · Cited by 36
“…receptor-related protein (LRP), a member of the low-density lipoprotein receptor family (LDLR), highly expressed on BBB (Bell et al., 2007), has been reported to possess the ability to facilitate transport of ligands across EC of the BBB (Bell et al., 2007; Shibata et al., 2000; Ito et al., 2006).”
BackgroundElfakhri, K. H., Abdallah, I. M., Brannen, A. D., & Kaddoumi, A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.01.020 · Cited by 35
Current and Emerging Pharmacological Targets for the Treatment of Alzheimer’s Disease
Morsy, A., & Trippier, P. C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190744 · Cited by 38
“It is likely that ApoE increases passage of A from blood to brain mediated by the low-density lipoprotein receptor-related protein (LRP) and with age, the LRP expression tends to decrease, leading to the increase of A deposits in the brain [110].”
BackgroundKumar, D., Sharma, A., & Sharma, L. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200203101828 · Cited by 38
Wainwright, L., Hargreaves, I. P., Georgian, A. R., Turner, C., Dalton, R. N., Abbott, N. J., Heales, S., & Preston, J. E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103236 · Cited by 39
“Multiple LDLR family members may be inhibited by RAP including vLDL-R, apoE receptor 2, LDL-R, and LRP-1 [72].”
BackgroundInfluentialBellaver, B., Puig‐Pijoan, A., Ferrari‐Souza, J. P., Leffa, D. T., Lussier, F. Z., Ferreira, P. C. L., Tissot, C., Povala, G., Therriault, J., Benedet, A. L., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13014 · Cited by 42
Ethell, D. W. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-130659 · Cited by 37
Banerjee, P., Sahoo, A., Anand, S., Bir, A., & Chakrabarti, S. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150514 · Cited by 39
Metabolite Clearance During Wakefulness and Sleep
Hladky, S. B., & Barrand, M. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_37 · Cited by 39
“2 mL g (1), measured values of the half-lives for these substances are in the range of 2–4 h (Shibata et al. 2000; Groothuis et al. 2007; Ball et al. 2010; Iliff et al. 2012) and the corresponding clearances are in the range of 0.”
InfluentialLiu, T., Lee, Y., Ko, C., Liu, R.-S., Ke, C., Lo, Y., Hong, P.-S., Chu, C., Chang, C.-W., Wu, P., et al. (2018) · Theranostics · doi:10.7150/thno.25625 · Cited by 38
“[6] hypothesized that there must be a clearance mechanism at the blood-brain barrier (BBB) to prevent Aβ accumulation and aggregation in the brain, and they have proven that low-density lipoprotein receptor–related protein-1 mediates transport of Aβ across the BBB to the periphery [7].”
BackgroundLaDu, M. J., Stine, Narita, M., Getz, G. S., Reardon, C. A., & Bu, G. (2006) · Biochemistry · doi:10.1021/bi051765s · Cited by 36
“similar to the clearance of R2-macroglobulin/Aâ complexes by LRP (14, 67).”
BackgroundPahnke, J., Fröhlich, C., Krohn, M., Schumacher, T., & Paarmann, K. (2013) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2013.08.007 · Cited by 38
“…interact with Apolipoprotein E variants (ABCA1) (Fitz et al., 2012) and membrane receptors such as LRP1/RAGE (low-density lipoprotein receptor-related protein/ receptor for advanced glycation end products) (Deane et al., 2003; Shibata et al., 2000) may also contribute to the ‘Aβ excretion highway’.”
BackgroundRole for apolipoprotein E in neurodegeneration and mercury intoxication
Lopez, M. E. C. (2017) · Frontiers in Bioscience-Elite · doi:10.2741/e819 · Cited by 37
“This breakdown of the integrity of the BBB found in ApoE4 individuals may permit the free entry of peripheral ApoE4 and mercury to the SNC, exacerbating the effects of these molecules in the intoxicated brain.”
BackgroundInfluentialHavekes, R., Heckman, P. R. A., Wams, E. J., Stasiukonytė, N., Meerlo, P., & Eisel, U. L. M. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109420 · Cited by 37
Ding, Y., Zhong, Y., Baldeshwiler, A., Abner, E. L., Bauer, B., & Hartz, A. M. S. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00245-4 · Cited by 35
Vascular contributions to cognitive impairment and dementia: the emerging role of 20-HETE
Gonzalez‐Fernandez, E., Liu, Y., Auchus, A. P., Fan, F., & Roman, R. J. (2021) · Clinical Science · doi:10.1042/cs20201033 · Cited by 41
Metabolic Diffusion in Neuropathologies: The Relevance of Brain-Liver Axis
Vegas‐Suárez, S., Simón, J., Martínez‐Chantar, M. L., & Moratalla, R. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.864263 · Cited by 40
Maximizing the Potential of Plasma Amyloid-Beta as a Diagnostic Biomarker for Alzheimer’s Disease
Oh, E. S., Troncoso, J. C., & Tucker, S. M. F. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8035-0 · Cited by 37
‘Alzheimer-like’ pathology in a murine model of arterial hypertension
Carnevale, D., & Lembo, G. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390939 · Cited by 34
Pan, Y., Xu, J., Chen, C., Chen, F., Jin, P., Zhu, K., Hu, C. W., You, M., Chen, M., & Hu, F. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00050 · Cited by 40
“In AD patients, the expression of LRP1 was down-regulated, while the expression of RAGE was up-regulated (Shibata et al., 2000; Deane et al., 2004), consistent with what we observed in AD rabbits.”
ResultA lymphatic waste-disposal system implicated in Alzheimer’s disease
Sweeney, M. D., & Zlokovic, B. V. (2018) · Nature · doi:10.1038/d41586-018-05763-0 · Cited by 35
Do angiotensin receptor blockers prevent Alzheimer's disease?
Hajjar, I. M., & Rodgers, K. E. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283620745 · Cited by 39
“About 10–15% of soluble Ab is diffused from the interstitial space into the cerebrospinal fluid and eventually to the bloodstream [42].”
BackgroundBanks, W. A., Kumar, V. B., Farr, S. A., Nakaoke, R., Robinson, S. M., & Morley, J. E. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100021 · Cited by 35
“Two BBB transporters have been implicated in A efflux, LRP-1 and P-gp [6] [7] [12] [13].”
Why study transport of peptides and proteins at the neurovascular interface
Pan, W., & Kastin, A. J. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.04.006 · Cited by 36
Uptake of Aβ 1–40- and Aβ 1–42-coated yeast by microglial cells: a role for LRP
Laporte, V., Lombard, Y., Levy-Benezra, R., Tranchant, C., Poindron, P., & Warter, J.-M. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.1203620 · Cited by 27
“To prevent neurotoxicity of A peptides, whichever their conformation and physical state, an organism can clear them using four mechanisms: transport of nfA and fA peptides in excess through the blood-brain barrier [5]; clearance of fA peptides through receptor-mediated endocytosis [6]; extracellular catabolism of nfA…”
BackgroundNeurovascular dysfunction in dementia – human cellular models and molecular mechanisms
Parkes, I., Chintawar, S., & Cader, M. Z. (2018) · Clinical Science · doi:10.1042/cs20160720 · Cited by 35
Genetic Variants and Oxidative Stress in Alzheimer’s Disease
Kowalska, M., Wize, K., Prendecki, M., Lianeri, M., Kozubski, W. P., & Dorszewska, J. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200224121447 · Cited by 36
Biomarkers Related to Endothelial Dysfunction and Vascular Cognitive Impairment: A Systematic Review
Martins, R., Zotin, M. C. Z., Rodrigues, G. R., & Pontes‐Neto, O. M. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000510053 · Cited by 39
Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases
Wilson, H., Politis, M., Rabiner, E. A., & Middleton, L. T. (2020) · Cells · doi:10.3390/cells9122581 · Cited by 37
“Dysfunction of the glymphatic system, in late life, has been shown to contribute to the accumulation of amyloid-β [304,305].”
BackgroundMahaman, Y. A. R., Huang, F., Salissou, M. T. M., Yacouba, M. B. M., Wang, J., Liu, R., Zhang, B., Li, H., Zhu, F., & Wang, X. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01356-6 · Cited by 35
Ito, S., Ohtsuki, S., Murata, S., Katsukura, Y., Suzuki, H., Funaki, M., Tachikawa, M., & Terasaki, T. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122077 · Cited by 34
“186 S. Ito et al. / IDE-Mediated monomer from rat brain to circulating blood [4, 5] and significantly reduced with aging in mouse and rat [5, 6] Therefore, modulation of the BBB elimination process for AD.”
Regulation of cholesterol efflux by amyloid β secretion
Umeda, T., Mori, H., Zheng, H., & Tomiyama, T. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22360 · Cited by 35
“In addition, clearing of apoE4 from mouse brain across the BBB is less efficient than for apoE2, apoE3, and Ab (Deane et al., 2008).”
BackgroundInfluentialMitochondrial mechanisms in amyloid beta peptide-induced cerebrovascular degeneration
Hsu, M., Sheu, J., Lin, C., Shen, M., & Hsu, C. Y. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.08.003 · Cited by 39
Smith, D. K., He, M., Zhang, C., & Zheng, J. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.006 · Cited by 37
Geyter, D. D., Smedt, A. D., Stoop, W., Keyser, J. D., & Kooijman, R. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12550 · Cited by 37
“The IGF-I receptor and LRP1, a variant of LRP2, are expressed in brain microvessels [33,34] and could be involved in this process.”
BackgroundZhou, J., Fonseca, M. I., Kayed, R., Hernandez, I., Webster, S. D., Yazan, O., Cribbs, D. H., Glabe, C. G., & Tenner, A. J. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-28 · Cited by 33
Antibodies to β-Amyloid Decrease the Blood-to-Brain Transfer of β-Amyloid Peptide1
Pan, W., Solomon, B., Maness, L. M., & Kastin, A. J. (2002) · Experimental Biology and Medicine · doi:10.1177/153537020222700808 · Cited by 34
Interactions between nanoparticles and pathological changes of vascular in Alzheimer’s disease
Lei, T., Yang, Z., Li, H., Qin, M., & Gao, H. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115219 · Cited by 36
Kim, S. Y., & Cheon, J. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102446 · Cited by 36
Schweinzer, C., Kober, A., Lang, I., Etschmaier, K., Scholler, M., Kresse, A., Sattler, W., & Panzenboeck, U. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110854 · Cited by 30
“In parallel to decreased intracellular A (cid:1) tetramer 6-fold) in pBCEC treated with simvastatin serum-free conditions (Fig.”
Metadata
- Authors
- Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., & Zlokovic, B. V.
- Affiliations
- University of Southern California (US)
- NYU Langone Health (US)
- Washington University in St. Louis (US)
- American Red Cross (US)
- University of Rochester Medicine (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2000-12-15
- Volume
- 106
- Issue
- 12
- Pages
- 1489-1499
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC387254
- OpenAlex
- W1997822484
- Cited by
- 1,413
- References
- 76
- Citations by year
- 2026: 38 · 2025: 60 · 2024: 58 · 2023: 59 · 2022: 57 · 2021: 75 · 2020: 85 · 2019: 73 · 2018: 52 · 2017: 67 · 2016: 64 · 2015: 56 · 2014: 60 · 2013: 62 · 2012: 60
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p01ag016223-04)
- National Institute on Aging (R37AG005891, R01AG013956, P50AG005142, AG16223, R37AG013956, AG05891)
- National Heart, Lung, and Blood Institute (R01HL050784)
- National Institute of Neurological Disorders and Stroke (NS 33466, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- Aβ40, Alzheimer's disease, blood-brain barrier, LDL receptor-related protein 1, receptor-associated protein, alpha2-macroglobulin, apolipoprotein E, amyloid-beta clearance, efflux transport, cerebral microvasculature, amyloid-beta deposition
- MeSH terms
- Aging, alpha-Macroglobulins, Alzheimer Disease, Amino Acid Sequence, Animals, Apolipoproteins E, Biological Transport, Blood-Brain Barrier, Brain, Catheterization, Genotype, Half-Life, Humans, Immunohistochemistry, Inulin, Iodine Radioisotopes, Kinetics, Male, Mice, Inbred C57BL, Molecular Sequence Data, Peptide Fragments, Receptors, Immunologic, Amyloid beta-Peptides, Mice, Knockout, Low Density Lipoprotein Receptor-Related Protein-1, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.






